The role of the ubiquitin-proteasome pathway in cardiovascular disease

Cardiovascular Research

Volumn 85, Issue 2, 2010, Pages 251-252

  Depre, Christophe ^a   Powell, Saul R ^b   Wang, Xuejun ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; UBIQUITIN;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL PROLIFERATION; EDITORIAL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 72949103905     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp362     Document Type: Editorial

References (27)

1. Ciechanover A, Heller H, Elias S, Haas A, Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 1980;77:1365-1368.
2. Rose IA, Warms JV, Hershko A. A high molecular weight protease in liver cytosol. J Biol Chem 1979;254:8135-8138.
3. de Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha. J Biol Chem 1998;273:23946-23951.
4. Folco E, Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J 1997;328:37-43.
5. Eble DM, Spragia ML, Ferguson AG, Samarel AM. Sarcomeric myosin heavy chain is degraded by the proteasome. Cell Tissue Res 1999;296:541-548.
6. Taylor RG, Tassy C, Briand M, Robert N, Briand Y, Ouali A. Proteolytic activity of proteasome on myofibrillar structures. Mol Biol Rep 1995;21:71-73.
7. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246: 243-248.
8. Kassiotis C, Ballal K, Wellnitz K, Vela D, Gong M, Salazar R et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009;120:S191-S197.
9. Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hyper-trophic cardiomyopathy. J Mol Biol 2008;384:896-907.
10. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn M. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003;3:208-216.
11. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006;6:129.
12. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008;88:219-222.
13. Su H, Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res 2010;85:253-262.
14. Dantuma NP, Lindsten K. Stressing the ubiquitin-proteasome system. Cardiovasc Res 2010;85:263-271.
15. Turner G, Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. Science 2000;289:2117-2120.
16. Fasanaro P, Capogrossi MC, Martelli F. Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. Cardiovacs Res 2010;85:272-280.
17. Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)func-tion. Cardiovasc Res 2010;85:281-290.
18. Herrmann J, Lerman LO, Lerman A. On the road to degradation: atherosclerosis and the proteasome. Cardiovasc Res 2010;85:291-302.
19. Powell SR, Divald A. The ubiquitin-proteasome system in myocardial ischaemia and preconditioning. Cardiovasc Res 2010;85:303-311.
20. Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010;85:312-320.
21. Hedhli N, Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 2010;85:321-329.
22. Hedhli N, Lizano P, Hong C, Fritzky L, Dhar S, Liu H et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 2008;295:H1385-H1393.
23. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X et al. Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res 2008;77:497-505.
24. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L et al. Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy. Circulation 2006;114:1821-1828.
25. Carrier L, Schlossarek S, Willis MS, Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res 2010;85:330-338.
26. Tsukamoto O, Minamino T, Kitakaze M. Functional alterations of cardiac protea-somes under physiological and pathological conditions. Cardiovasc Res 2010;85: 339-346.
27. Luo H, Wong J, Wong B. Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy. Cardiovasc Res 2010;85:347-356.